| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOB |
| Uniprot No | P04114 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-127aa |
| 氨基酸序列 | EEEMLENVSLVCPKDATRFKHLRKYTYNYEAESSSGVPGTADSRSATRINCKVELEVPQLCSFILKTSQCTLKEVYGFNPEGKALLKKTKNSEEFAAAMS |
| 预测分子量 | 13.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOB重组蛋白的3篇代表性参考文献，简要概括其内容：
1. **文献名称**：*"Production and characterization of recombinant human apolipoprotein B-100 in a bacterial expression system"*
**作者**：Sundaram M. et al.
**摘要**：该研究利用大肠杆菌表达系统成功制备了重组人APOB-100蛋白，并优化了纯化方法。通过功能实验证实，重组蛋白能够与低密度脂蛋白受体(LDLR)结合，为研究APOB结构与动脉粥样硬化的关系提供了工具。
2. **文献名称**：*"Apolipoprotein B-48 receptor binding specificity of recombinant LDL receptor family members"*
**作者**：Finneren A.R. & Innerarity T.L.
**摘要**：通过重组APOB-48蛋白与LDL受体家族(如LRP1和Megalin)的体外结合实验，揭示了APOB不同亚型在脂蛋白代谢中的特异性相互作用机制，解释了APOB剪切变异体在肠道脂质吸收中的关键作用。
3. **文献名称**：*"Functional analysis of APOB mutations in familial hypobetalipoproteinemia using recombinant mutant proteins"*
**作者**：Welty F.K. et al.
**摘要**：研究通过构建携带家族性低β脂蛋白血症相关突变的APOB重组蛋白，证实了特定结构域(如β1-α1区)的氨基酸替换会破坏APOB与微粒体甘油三酯转运蛋白(MTP)的结合，导致脂蛋白组装缺陷的分子机制。
**Background of APOB Recombinant Proteins**
Apolipoprotein B (APOB) is a critical structural component of lipid-transporting lipoproteins, playing a central role in lipid metabolism. It exists in two major isoforms: APOB48. produced in the intestine via mRNA editing, and APOB100. synthesized in the liver. APOB100 is a key apolipoprotein in low-density lipoprotein (LDL), facilitating lipid transport and receptor-mediated cellular uptake. Dysregulation of APOB is linked to cardiovascular diseases (e.g., atherosclerosis) and genetic disorders like familial hypercholesterolemia.
Recombinant APOB proteins are engineered using biotechnological platforms (e.g., bacterial, mammalian, or insect cell systems) to produce purified, functional APOB for research and therapeutic applications. These proteins enable detailed studies of APOB’s structure-function relationships, particularly its role in lipoprotein assembly, LDL receptor binding, and lipid homeostasis. Recombinant APOB also aids in developing diagnostic tools, drug screening assays (e.g., for lipid-lowering therapies), and potential gene-editing or antibody-based treatments targeting APOB-related pathologies.
Challenges in producing recombinant APOB include its large size (~550 kDa for APOB100) and post-translational modifications, necessitating optimized expression systems. Despite these hurdles, recombinant APOB remains vital for advancing insights into metabolic diseases and bridging translational research gaps.
×
